Zimbabwe has rejected a substantial American healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to the United States' demand for sensitive data.
The decision came to light after a official document dated December was leaked, which showed Head of State Emmerson Mnangagwa deemed the arrangement was "unbalanced".
A government representative has since explained that the United States was seeking genetic material for scientific study and commercial gain while was not willing to share the benefits from future vaccines.
"We must now begin the challenging and unfortunate task of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for more negotiations to reach a deal acceptable to all parties so the nation's vital HIV programme can be sustained.
Wider Context
Zimbabwe's decision follows a similar case in Kenya, where a high court halted a related deal with the US after legal challenges were raised about the security of citizens' health data.
After returning to the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump stated its spending was "inefficient" and his government was seeking government-to-government deals to boost transparency and accountability.
Based on statements, 16 nations in Africa have so far agreed to these new agreements, representing over $18.3bn in new funding.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation would have delivered extraordinary benefits for Zimbabwean communities, particularly the 1.2 million currently receiving HIV treatment via American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, without any equivalent guarantee of benefiting from any medical innovations – such as new medicines or tests – that might result from that shared data," his statement read.
"Put simply, our country would provide the raw materials for medical research without any assurance that the resulting innovations would be available to our people should a future disease outbreak arise."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the global health body and its pursuit of one-on-one health agreements were disrupting systems previously established via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This framework is designed to ensure that when a nation provides its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to develop them."
The government's concerns regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how future co-operation could be structured in a manner that honours the sovereignty and dignity of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but urged that talks must proceed considering a large portion of the nation's HIV programmes relied on foreign aid.
"In cases where technical issues exist, including those involving information security or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," it added.
This impasse emphasises the continuing challenges between receiving vital international aid and protecting a country's data in an increasingly data-driven world.